Ketanov injection for 30mg ml ampoule 1ml N10
Condition: New product
989 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Ketorolac
Release form
Solution
Composition
1 ml of solution (1 ampoule) contains: Active ingredient: Ketorolaka tromethamine 30 mg.
Pharmacological effect
NPVS, pyrrolizin-carboxylic acid derivative. It has a pronounced analgesic effect, also has anti-inflammatory and moderate antipyretic effect. The mechanism of action is associated with inhibition of the activity of COX - the main enzyme in the metabolism of arachidonic acid, which is a precursor of prostaglandins, which play a major role in the pathogenesis of inflammation, pain and fever.
Pharmacokinetics
When ingestion is absorbed from the gastrointestinal tract. Cmax in plasma is reached in 40-50 minutes both after oral administration and after i / m administration. Food intake does not affect absorption. Plasma protein binding is more than 99% .T1 / 2 - 4-6 hours both after oral administration and after i / m administration. More than 90% of the dose is excreted in the urine, in unchanged form - 60%; the rest is through the intestines. In patients with impaired renal function and seniors, the elimination rate decreases, T1 / 2 increases.
Indications
Short-term relief of pain of various origins, including: postoperative pain (including after abdominal, gynecological, orthopedic operations), pain in sprains, fractures and injuries of soft tissues, toothache (including after surgical dental interventions); pain in the postpartum period; pain in cancer; pain in osteoarthritis; ischialgia. Ketanov is not indicated for use in chronic pain.
Contraindications
gastric ulcer and duodenal ulcer in the acute phase, gastrointestinal bleeding, bronchial asthma, severe cerebrovascular disorders, moderate and severe renal impairment, the risk of developing renal failure in hypovolemia and dehydration, coagulation disorders in anamnesis, and hemorrhage; reception with other NSAIDs; children and adolescents up to 16 years; hypersensitivity to ketorolac and other NSAIDs.
Precautionary measures
Do not exceed recommended doses.
Use during pregnancy and lactation
Contraindicated during pregnancy, during childbirth and during lactation (breastfeeding). Ketorolac is contraindicated for use as a premedication agent, supportive anesthesia and for anesthesia in obstetric practice, because under its influence may increase the duration of the first stage of labor. In addition, ketorolac can inhibit uterine contractility and fetal blood circulation.
Dosage and administration
The maximum duration of the use of the solution for injection is 2 days. The maximum daily dose of the drug (for any dosage form) is 90 mg. For patients with body weight up to 50 kg, people over 65 years of age and patients with impaired renal function, the maximum daily dose is 60 mg
Side effects
On the part of the digestive system: stomatitis, nausea, constipation, dyspepsia, gastritis, erosive and ulcerative gastrointestinal lesions, dry mouth. On the side of the central nervous system and peripheral nervous system: drowsiness, dizziness, nervousness, paresthesia. On the part of the urinary system: frequent urination, acute renal failure, nephrotic syndrome, interstitial nephritis. Metabolism: increased creatinine and / or urea in the blood plasma. From the water and electrolyte balance: hypokalemia, hyponatremia. On the side of cardiovascular systems: bradycardia, changes in blood pressure. From the blood coagulation system: thrombocytopenia, purpura, hematomas, nasal bleeding, lengthening of the clotting time. From the respiratory system: odes shka.Allergichesky reactions: urticaria. Others: thirst.
Overdose
Overdose of the drug is not described.
Interaction with other drugs
With the simultaneous use of Ketorolak with other NSAIDs, additive side effects may develop; with pentoxifylline, anticoagulants (including low-dose heparin) - may increase the risk of bleeding; with ACE inhibitors - may increase the risk of developing renal dysfunction; with probenecid - plasma ketorolac concentration and its half-life increase; with lithium preparations, a decrease in the renal clearance of lithium and an increase in its concentration in plasma is possible; with furosemide - reducing its diuretic action. When using Ketorolac, the need for the use of opioid analgesics for the purpose of pain relief is reduced.
special instructions
It is used with caution in patients with impaired liver and kidney function, chronic heart failure, arterial hypertension, in patients with erosive and ulcerative lesions of the gastrointestinal tract and bleeding from the gastrointestinal tract in anamnesis. (including after resection of the prostate gland, tonsillectomy, in cosmetic surgery), as well as in elderly patients, since the half-life of ketorolac is lengthened, and plasma clearance may be reduced. In this category of patients, it is recommended to use Ketorolac in doses close to the lower limit of the therapeutic range. If symptoms of liver damage, skin rash, eosinophilia, ketorolac should be canceled. Ketorolac is not indicated for use in chronic pain syndrome. Effects on the ability to drive vehicles and control mechanismsIf drowsiness, dizziness, insomnia or depression appear during the treatment with Ketorolac, you must take extra caution during classes of potentially dangerous activities that require increased attention and speed of psychomotor reactions.